On July 30, "Shandong Workers' News" published a newsletter entitled "Zhang Haijun: Ingenuity to protect the health of patients", with nearly 1,600 words, systematically reported on the director of Shandong Baiduoan Medical Equipment Co., Ltd. in our county Chang Zhang Haijun, a leader in medical device scientific research, has been in obscurity for more than ten years, devoted himself to research, aimed at the world's cutting-edge medical device technology with the spirit of craftsmanship, developed a series of new products, broke the monopoly of foreign products, and relieved the pain of patients. At the same time, it also saves a lot of costs for patients, so that many patients are reborn.
The editor below shares and read the report with you
Zhang Haijun: Ingenuity protects the health of patients
Recently, a movie "I am not the god of medicine" has spread all over the country. The real situation of the difficulty and expensive medical treatment of ordinary people hurts the hearts of the audience. They are looking forward to when we will be able to use good medicines that are cheap and effective. Everyone Have a healthy body.
In Qihe, there is such a leader in medical device scientific research. For more than ten years, he has been in obscurity, devoted himself to research, aimed at the world's cutting-edge technology of medical devices with the spirit of craftsmanship, developed a series of new products, broke the monopoly of foreign products, and relieved the pain of patients while also saving a lot of costs for patients. So many patients are reborn.
He is Zhang Haijun, a representative of the 13th National People's Congress, the chief scientist of the National 863 Program and the key research and development program, a model worker of Dezhou City, and the chairman of Shandong Baiduoan Medical Equipment Co., Ltd.
Study abroad and serve the country by starting a business
Zhang Haijun, 50 years old this year, has a wealth of personal experience. After graduating from university, he engaged in medical research and clinical work in Beijing Jishuitan Hospital, and later joined the German Bayer Company as a product manager. In 1999, he entered the California State Public University to participate in EMBA training.
In 1997, Zhang Haijun served as the regional manager of Bayer in Germany. As the backbone of a large multinational company, not only are they well-paid, they are also trained by the top management as a key reserve force. What he presents is a golden avenue, which can be described as smooth and promising.
But Zhang Haijun made a jaw-dropping decision-resign! The president of the company personally communicated with him, hoping that he would stay, and promised him good terms, but he still resolutely chose to leave. He saw that the domestic mid-to-high-end medical device market has been monopolized by large foreign companies. Not only are we unable to master the core technology, but consumers also face a heavy burden of high prices. He wants to change all of this.
So he went to the United States to learn the most advanced medical technology in the world. Here, his professional knowledge has been fully expanded, and his grasp of the research and development trend of biomaterials has improved to a level, laying a good foundation for Zhang Haijun to enter the biomedical industry in the future. At the end of the study, he declined the high salary retention of many multinational companies in the United States and returned to start a domestic business. In 2003, Shandong Baiduoan Medical Equipment Co., Ltd. settled in Qihe.
Innovation first, leading the world
Interventional catheters are a common medical device that is indispensable for cancer patients during chemotherapy. The amount of clinical use is very large, but who knows that seemingly inconspicuous small catheters have been monopolized by American products until 2011, despite this This kind of catheter has the shortcomings of being easy to break and causing secondary operations.
Zhang Haijun led the scientific research team to target this project and was determined to develop their own products. After thousands of material process optimization experiments, they finally solved this problem and broke the foreign monopoly. In July 2011, the peripheral central venous intervening catheter obtained national certification and completed the localization of PICC products. The performance is better than imported products, filling the domestic gap, and the clinical use effect is good.
my country is an area with a high incidence of heart disease. As many as 3 million patients die of heart disease each year, and the rate is increasing by 20% every year. However, due to the high price of stents, the annual number of operations in my country is only four to five million. Only a small percentage of patients.
At present, domestic and foreign manufacturers mostly use polylactic acid as the stent material, which has insufficient support, which can easily lead to thrombosis, local inflammation, and is not easy to degrade. "Postoperative restenosis is one of the main challenges it faces. To solve this problem is to develop a degradable stent to reduce the irritation caused by the long-term residual blood vessels of foreign bodies, and to reduce the use of long-term intensive antiplatelet therapy. If restenosis occurs or intervention is required again , The treatment is relatively easy." Zhang Haijun said.
"Zinc alloy stents are currently in the basic research stage abroad, and we have completed animal experiments and will enter human clinical trials in 2019. This core technology has applied for international patent protection and is expected to develop the world's first degradable zinc alloy crown. Pulse stent products. In this field, it has realized the transformation from the original follower to the leader." Zhang Haijun told reporters.
Build a nest to attract phoenix
Zhang Haijun embraces a heart of peach and plum, and shares what he has learned, researched, and gained with others as much as possible. He has been hired as a guest professor by Tongji University, Southwest Jiaotong University, Shandong University of Science and Technology, etc., and has been invited to the university many times to teach business management innovation and talent training experience. At the same time, many undergraduates, masters and doctoral students from home and abroad are actively admitted to the company's production base, R&D center and engineering technology center for internships, training batches of innovative talents.
In order to better retain talents, the expert apartment and employee activity center proposed by Zhang Haijun in 2017 have been put into use one after another. Employees have activities and entertainment venues outside of work, and they have a sense of belonging. At present, the company’s R&D team includes 1 national "Ten Thousand Talents Program" leader, 1 national "Thousand Talents Program" expert, 2 Taishan industry leaders, 1 academician of the Chinese Academy of Sciences, 2 National Youth Thousand Talents Program, 6 doctors, There are 30 masters, and the research level is at the international advanced level. Zhang Haijun was also selected as an innovative entrepreneur in the National "Ten Thousand Talents Plan", an expert in the "National Innovative Talent Promotion Plan", and a Taishan Scholar.
Contributor: Yang Xuexue